Evidence map›Paper›PMID 36550146›Full record

ArticleScientific reports2022

The prospective effect of fucoidan on splenic dysfunction caused by oxaliplatin in male rats through endoplasmic stress dynamics.

Eman H Basha, Amira M ElShamy, Hoda A Ibrahim, Mohamed A Safa, Nehal A E Heabah, Radwa Awad, Radwa Ismail, Rabab M Amer, Ola M Salem, Heba Faheem and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Eman H BashaDepartment of Medical Physiology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Amira M ElShamyDepartment of Medical Biochemistry, Faculty of Medicine, Tanta University, Tanta, Egypt.
Hoda A IbrahimDepartment of Medical Biochemistry, Faculty of Medicine, Tanta University, Tanta, Egypt.
Mohamed A SafaDepartment of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
Nehal A E HeabahDepartment of Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Radwa AwadDepartment of Clinical Oncology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Radwa IsmailDepartment of Anatomy, Faculty of Medicine, Tanta University, Tanta, Egypt. radwa.ismael@med.tanta.edu.eg.
Rabab M AmerDepartment of Anatomy, Faculty of Medicine, Tanta University, Tanta, Egypt.
Ola M SalemDepartment of Medical Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Heba FaheemDepartment of Medical Physiology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Yasmeen M El-HartyDepartment of Medical Physiology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Tanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fucoidans (FUCs) are highly sulfated polysaccharides demonstrating multiple actions in different systems. Oxaliplatin (OXA) is a platinum-containing chemotherapeutic agent with several side effects that restrict its usage. The current study aimed to determine the potential effect of FUC in male rats with splenic dysfunction induced by OXA. Eighty adult male rats aged (8-9 weeks) weighing (190-230 g) were divided into four groups: (Group I: the control group): Rats were administrated normal saline; (Group II: controls treated by FUC): Rats were treated with FUC; (Group III: Splenic dysfunction group): Rats were treated with 8 mg/kg OXA. (IV: Splenic dysfunction treated by FUC): Rats were treated by OXA as Group III, then fucoidan was given. At the end of the experiment, blood was collected to determine red blood cells and white blood cells. Splenic tissues were divided into one part for biochemical assays, oxidative stress markers as MDA and catalase, inflammatory markers (TNF-alpha, IL6), and apoptotic markers (caspase 3) and gene expression of Nrf2, Mapk1 gene expression, and endoplasmic stress parameters and the other part was used for immunohistochemical and histopathological analysis. Compared to the OXA-induced splenic dysfunction group, FUC significantly decreased high levels of MDA, TNF- alpha, IL6, caspase-3, Mapk1, endoplasmic stress induced by OXA, and increased the level of catalase and Nrf2. Fucoidan has corrected the histopathological and immunohistochemical changes compared to the OXA-induced splenic dysfunction group. In conclusion, our findings suggest that fucoidan has a significant role in the treatment of splenic dysfunction induced by OXA.

Indexed as

Interleukin-6NF-E2-Related Factor 2AnimalsCatalaseMaleOxaliplatinOxidative StressPolysaccharidesProspective StudiesRatsCatalasefucoidanInterleukin-6NF-E2-Related Factor 2OxaliplatinPolysaccharides

Identifiers

PMID36550146
PMCPMC9780252
OpenAlexW4312075191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.